All In Biotech

Drug Trial Radar · NCT06817343

A Long-term Follow up Study of EXG102-031 in Patients With wAMD (Everest LTFU)

An Open-label, Long-term Follow-Up Study to Evaluate the Safety and Tolerability of Gene Therapy With EXG102-031 in Participants With Neovascular Age-related Macular Degeneration

Last checked: Nov 20, 2026Latest source record: Apr 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

12

Planned (sponsor's estimate)

Start

Sep 10, 2024

Primary completion

Feb 2029

Study completion Feb 2029

Sponsor

Lead sponsor
Exegenesis BioIndustry
Sponsor type
Industry
First posted
Feb 10, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In neovascular (wet) age-related macular degeneration (nAMD), the macula, or the part of the eye that provides the clear, detailed central vision, is being affected by abnormal blood vessel growth and leakage. This leakage affects the vision over time and can lead to severe blurriness or blinding. EXG102-031 was made to block the extra vessel formation which would lead to less leakage affecting the vision. Before EXG102-031 can be tested for its efficacy (if it makes vision better), it must be tested to see if it is safely tolerated to confirm it can continue to be studied in more patients with nAMD. This study is designed to fulfill the long-term safety monitoring of EXG102-031. Participants that enroll in this long-term follow-up study have been treated with EXG102-031 under the main study (EXG102-031-211).

Conditions

  • Neovascular Age-Related Macular Degeneration (nAMD)
  • Neovascular (Wet) Age-related Macular Degeneration (AMD)

Interventions

  • Aflibercept (2.0 mg)Biological

    PRN IVT Aflibercept

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluation of long-term safety by measuring frequency, type, and intensity of ocular and non-ocular adverse events (AEs) and serious adverse events (SAEs) through Month 36 (Year 4) post EXG102-031 administration.Time frame: Month 36

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Sierra Eye Associates

    Reno, Nevada

  • Erie Retina Research

    Erie, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.